Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

May 14, 2020

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

May 12, 2020

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

May 11, 2020

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

May 08, 2020

Charles L. Sawyers, MD, discusses the implications of the IMbassador250 trial, other notable presentations delivered at the meeting, and exciting research efforts being made in prostate cancer and beyond.

April 30, 2020

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

April 29, 2020

Ariela Noy, MD, discusses the rationale and design of the phase 2 study of devimistat in patients with aggressive lymphoma.

April 21, 2020

Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.

April 16, 2020

Anthony R. Mato, MD, MSCE, discusses the different research efforts that are being made with immunotherapy in chronic lymphocytic leukemia.

April 16, 2020

Data from the phase II FIGHT-202 study of pemigatinib in advanced or metastatic FGFR2-positive cholangiocarcinoma have been published as the FDA considers a new drug application for the treatment in this setting.

April 14, 2020

Yelena Y. Janjigian, MD, discusses results from the phase III JAVELIN Gastric 100 study evaluating avelumab in gastric or gastroesophageal cancer.

April 14, 2020

Eileen O'Reilly, MD, discusses the potential role of veliparib in pancreatic cancer.

April 14, 2020

David H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric cancers.

April 11, 2020

Ghassan K. Abou-Alfa, MD, discusses sequencing challenges in metastatic hepatocellular carcinoma.

April 10, 2020

Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.

April 08, 2020

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

April 07, 2020

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

April 03, 2020

Ghassan K. Abou-Alfa, MD, discusses the most intriguing updates in hepatocellular carcinoma, anticipated sequencing challenges, and novel modalities on the horizon.

April 03, 2020

Gopa Iyer, MD, discusses the challenges faced with identifying an optimal screening methodology to select patients with bladder cancer for FGFR inhibitor therapy.

April 02, 2020

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

April 01, 2020

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the updated results of the phase Ib/II EV-103 trial (NCT03288545) with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial carcinoma.